Beyond Recycling Antibodies: Crovalimab's Molecular Design Enables Four-Weekly Subcutaneous Injections for PNH...

Area of Science:

• Immunology
• Pharmacology
• Biochemistry

Background:

• Recycling antibodies enhance therapeutic durability and reduce dosage frequency.
• Eculizumab and ravulizumab are C5 inhibitors for paroxysmal nocturnal hemoglobinuria (PNH), but have limitations.
• Intravenous administration and genetic polymorphism (R885H SNP) affect C5 inhibitor efficacy.

Purpose of the Study:

• To introduce crovalimab, a next-generation recycling antibody designed to overcome existing limitations.
• To highlight crovalimab's innovative charge engineering and unique C5 epitope targeting.
• To evaluate crovalimab's efficacy, pharmacokinetic profile, and suitability for subcutaneous delivery.

Main Methods:

• Molecular characterization of crovalimab, including Fcγ receptor and C1q binding.
• Assessment of antigen binding characteristics and cellular uptake of C5-crovalimab complexes.
• In vivo studies in mice to evaluate C5 clearance and comparison with existing recycling antibodies.

Main Results:

• Crovalimab exhibits eliminated binding to Fcγ receptors and C1q, with optimized antigen binding.
• Charge engineering enhances cellular uptake and allows efficacy irrespective of the R885H SNP.
• Crovalimab demonstrates faster C5 clearance in mice and neutralizes approximately seven C5 molecules per antibody in vivo.
• Reduced viscosity facilitates high-concentration formulations for subcutaneous administration.

Conclusions:

• Crovalimab represents a significant advancement in C5 inhibition for PNH treatment.
• Its design overcomes limitations of previous therapies, offering improved efficacy and convenience.
• The four-weekly subcutaneous injection regimen has the potential to transform patient quality of life.